• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract Panobinostat, lenalidomide, bortezomib, and dexamethasone was well-tolerated and showed potential in treating relapsed/refractory multiple myeloma

byKathleen Lau
February 25, 2021
in StudyGraphics
0
Share on FacebookShare on Twitter

RELATED REPORTS

Intraarterial dexamethasone may be effective for pain relief following uterine fibroid embolization

Younger age and systemic metastases may independently predict survival among patients with choroidal metastases

2 Minute Medicine Rewind August 3rd, 2026

Tags: bloodblood cancerbortezomibcancerdexamethasonedose limiting toxicityhematologylenalidomidemultiple myelomaoncologypanobinostatperipheral neuropathyrelapsed refractory multiple myeloma
Previous Post

Higher SARS-CoV-2 infection rate in pregnant patients

 Next Post

#VisualAbstract: Female sex may be associated with better overall and disease-specific survival in Merkel cell carcinoma

RelatedReports

Elagolix with add-back hormone therapy effective in reducing fibroid-associated menstrual bleeding
Chronic Disease

Intraarterial dexamethasone may be effective for pain relief following uterine fibroid embolization

August 5, 2026
Adalimumab aids in control of noninfectious uveitis
Chronic Disease

Younger age and systemic metastases may independently predict survival among patients with choroidal metastases

August 3, 2026
Elagolix with add-back hormone therapy effective in reducing fibroid-associated menstrual bleeding
Weekly Rewinds

2 Minute Medicine Rewind August 3rd, 2026

August 3, 2026
Variability in interpretation of breast biopsy slides associated with low verification of atypia and ductal carcinoma in situ
Chronic Disease

A digital mental health intervention may improve anxiety in breast cancer survivors

July 31, 2026
Next Post
#VisualAbstract: Female sex may be associated with better overall and disease-specific survival in Merkel cell carcinoma

#VisualAbstract: Female sex may be associated with better overall and disease-specific survival in Merkel cell carcinoma

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Transdermal estrogen shows similar cardiovascular safety profile to traditional luteinizing hormone therapy in patients with prostate cancer

#VisualAbstract Asciminib is shown to be safe and efficacious in clinical practice for treating patients with chronic myeloid leukemia

#VisualAbstract Asciminib is shown to be safe and efficacious in clinical practice for treating patients with chronic myeloid leukemia

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • A health coaching intervention may improve blood pressure control in postpartum women
  • Surgery is associated with an increased quality of life in women with endometriosis
  • Bougie-guided and stylet-guided intubation may have similar success rate in the intubation of trauma patients
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • RVU Search
    • NPI Registry Lookup
  • Pharma
  • AI News
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.